Hospital District of Satakunta
Satakunnan sairaanhoitopiiri
Finland
1 June 2019 - 31 May 2020
Region: Global
Subject/journal group: All
The table to the right includes counts of all research outputs for Hospital District of Satakunta published between 1 June 2019 - 31 May 2020 which are tracked by the Nature Index.
Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
| Count | Share |
|---|---|
| 2 | 0.01 |
Outputs by subject (Share)
| Subject | Count | Share | |
|---|---|---|---|
| Life Sciences | 2 | 0.01 | |
Top articles by Altmetric score in current window
Genetic architecture of human plasma lipidome and its link to cardiovascular disease
Nature Communications
2019-09-24
1 June 2019 - 31 May 2020
International vs. domestic collaboration by Share
- 60.38% Domestic
- 39.62% International
Note: Hover over the graph to view the percentage of collaboration.
Top 10 domestic collaborators by Share (32 total)
- Hospital District of Satakunta, Finland
- Domestic institution
-
Institute for Molecular Medicine Finland (FIMM), Finland
(0.26)
-
The Hospital District of Helsinki and Uusimaa (HUS), Finland
(0.19)
-
Finland Ministry of Social Affairs and Health, Finland
(0.19)
-
Northern Ostrobothnia Hospital District (NOHD), Finland
(0.11)
-
University of Eastern Finland (UEF), Finland
(0.10)
-
University of Helsinki, Finland
(0.09)
-
Pirkanmaa Hospital District, Finland
(0.09)
-
Hospital District of Southwest Finland, Finland
(0.08)
-
Medical Research Center Oulu (MRC Oulu), Finland
(0.07)
-
VTT Technical Research Centre of Finland Ltd., Finland
(0.06)
Top 10 international collaborators by Share (20 total)
- Hospital District of Satakunta, Finland
- Foreign institution
-
F. Hoffmann-La Roche AG, Switzerland
(0.16)
-
AbbVie Inc., United States of America (USA)
(0.15)
-
Pfizer Inc., United States of America (USA)
(0.12)
-
Merck & Co., Inc., United States of America (USA)
(0.12)
-
GlaxoSmithKline plc. (GSK), United Kingdom (UK)
(0.09)
-
Sanofi, France
(0.07)
-
Biogen Inc., United States of America (USA)
(0.07)
-
Bristol-Myers Squibb (BMS), United States of America (USA)
(0.06)
-
European Molecular Biology Laboratory (EMBL), Germany
(0.06)
-
AstraZeneca plc, United Kingdom (UK)
(0.04)
Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.
Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
